

Effect of telemonitoring and telerehabilitation on physical activity, exercise capacity, health-related quality of life and healthcare use in patients with chronic lung diseases or COVID-19: A scoping review

Journal of Telemedicine and Telecare

2024, Vol. 30(7) 1097–1115

© The Author(s) 2022



Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/1357633X221122124

journals.sagepub.com/home/jtt



Diana C Sanchez-Ramirez¹ , Margriet Pol², Hal Loewen³ 
and Mohamed-Amine Choukou⁴ 

Abstract

Background: Telemonitoring and telerehabilitation can support home-based pulmonary rehabilitation (PR) and benefit patients with lung diseases or COVID-19. This study aimed to (1) identify which telemonitoring and telerehabilitation interventions (e.g. videoconferencing) are used to provide telehealth care for people with chronic respiratory conditions or COVID-19, and (2) provide an overview of the effects of telemonitoring and telerehabilitation on exercise capacity, physical activity, health-related QoL (HRQoL), and healthcare use in patients with lung diseases or COVID-19.

Methods: A search was performed in the electronic databases of Ovid MEDLINE, EMBASE, and Cinahl through 15 June 2021. Subject heading and keywords were used to reflect the concepts of telemonitoring, telerehabilitation, chronic lung diseases, and COVID-19. Studies that explored the effect of a telerehabilitation and/or telemonitoring intervention, in patients with a chronic lung disease such as asthma, chronic obstructive pulmonary diseases (COPD), or COVID-19, and reported the effect of the intervention in one or more of our outcomes of interest were included. Excluding criteria included evaluation of new technological components, teleconsultation or one-time patient assessment.

Results: This scoping review included 44 publications reporting the effect of telemonitoring (25 studies), telerehabilitation (8 studies) or both (11 studies) on patients with COPD (35 studies), asthma (5 studies), COPD and asthma (1 study), and COVID-19 (2 studies). Patients who received telemonitoring and/or telerehabilitation had improvements in exercise capacity in 9 out of 11 (82%) articles, better HRQoL in 21 out of 25 (84%), and fewer health care use in 3 out of 3 (100%) articles compared to pre-intervention. Compared to controls, no statistically significant differences were found in the intervention groups' exercise capacity in 5 out of 6 (83%) articles, physical activity in 3 out of 3 (100%) articles, HRQoL in 21 out of 25 (84%) articles, and healthcare use in 15 out of 20 (75%) articles. The main limitation of the study was the high variability between the characteristics of the studies, such as the number and age of the patients, the outcome measures, the duration of the intervention, the technological components involved, and the additional elements included in the interventions that may influence the generalization of the results.

Conclusion: Telemonitoring and telerehabilitation interventions had a positive effect on patient outcomes and appeared to be as effective as standard care. Therefore, they are promising alternatives to support remote home-based rehabilitation in patients with chronic lung diseases or COVID-19.

Keywords

Telerehabilitation, home telecare, telecare, ehealth, telehealth, telemonitoring, COVID-19, COPD

Date received: 8 March 2022; Date accepted: 4 August 2022

¹Department of Respiratory Therapy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

²Department of Occupational Therapy, Faculty of Health, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences, The Netherlands

³Neil John Maclean Health Sciences Library, University of Manitoba, Canada

⁴Department of Occupational Therapy, Rady Faculty of Health Science, University of Manitoba, Canada

Corresponding author:

Diana C. Sanchez-Ramirez, Department of Respiratory Therapy, Rady Faculty of Health Sciences, R334-771 McDermot Ave, University of Manitoba, Winnipeg, MB R3E 0T6 Canada.

Email: diana.sanchez-ramirez@umanitoba.ca

Introduction

Chronic lung diseases and COVID-19 are leading causes of disease, death and disability globally^{1–4} which entail a substantial burden on the individual^{5–7} and healthcare systems.^{8,9} Pulmonary rehabilitation (PR) is defined by the “National Heart, Lung, And Blood Institute” as a “supervised program that includes exercise training, health education, and breathing techniques for people who have certain lung conditions or lung problems due to other conditions”¹⁰ is widely recognized as an important treatment for patients suffering from chronic respiratory diseases,^{11,12} and has been recommended as a potential beneficial intervention for post-COVID-19 patients.¹³ PR has been shown to provide statistically and clinically significant improvements in physical activity, exercise capacity, self-efficacy, and health-related quality of life (HRQoL), and a decrease in healthcare use in patients with lung diseases.^{11,14} Despite the multiple benefits identified, it has been estimated that less than 3% of people with chronic lung diseases accessed PR programs¹⁵ which are also hampered by low participation, insufficient attendance, and high dropout rates.^{16–19} Home-based PR programs seem to offer a promising alternative^{20,21} to overcome well-known PR barriers including, but not limited to, symptom severity, acute exacerbations, transportation, financial difficulties, disruption of daily routines and access to care in remote locations.^{17,18,22–25} In addition, the COVID-19 pandemic has highlighted the need for delivering PR programs remotely, safely, and efficiently.¹⁵

Advances in technology have boosted at-home health service delivery^{26,27} and popularized telehealth for those

with chronic diseases.^{27–30} Telehealth can be described as the use of electronic information and communication technology by professional health care providers to provide and support at-home health care to patients in case of long distances.³¹ Evidence indicates that telehealth can enhance healthcare use,^{32,33} especially among the populations who cannot otherwise access care.³⁴ There are several terms used to describe telehealth systems based on their applications. Telerehabilitation is defined as the delivery of rehabilitation services (e.g. assessment, prevention, treatment, education, and counseling) via information and communication technologies.³⁵ It has been associated with lower healthcare costs compared with traditional inpatient or person-to-person rehabilitation.^{36,37} Recent advances in sensor technology have also enabled remote patient telemonitoring, which is the transmission of physiological and other noninvasive data (e.g. heart rate, blood pressure, oxygen saturation, weight, symptoms, etc.) directly to care providers via Bluetooth or digital/broadband/wireless.^{36,38} Telemonitoring can be used to recognize and treat changes in the patient’s health status as a stand-alone approach (e.g. early detection) or as part of a telerehabilitation intervention. This paper focuses on telemonitoring and telerehabilitation as types of telehealth that can support home-based PR and benefit patients with lung diseases or COVID-19. The purpose of this paper is to depict the use of telemonitoring and telerehabilitation interventions in patients with chronic lung diseases, such as asthma, chronic obstructive pulmonary diseases (COPD), or COVID-19 patients and their association with patient health outcomes. The objectives of this paper were to (1) identify which telemonitoring and telerehabilitation interventions (e.g. videoconferencing) are used to provide telehealth care for people with chronic respiratory conditions or COVID-19, and (2) provide an overview of the effects of telemonitoring and telerehabilitation on exercise capacity, physical activity, HRQoL, and healthcare use in patients with lung diseases or COVID-19.

Methods

A health sciences librarian (HL), in consultation with the research team, developed and performed a search in the electronic databases of Ovid MEDLINE, EMBASE, and Cinahl through 15 June 2021. Subject heading and keywords were used to reflect the concepts of telemonitoring, telerehabilitation, chronic lung diseases, and COVID-19 (see supplement 1 for the OVID Medline search). The search was limited to full-text articles published in the English language with full text available. This scoping review of the literature, which has not been registered, was conducted using Preferred Items for Systematic Reviews and Meta-Analysis (PRISMA) (Figure 1). The search retrieved 3013 references. After removing the duplicates, two researchers screened 2941 titles and abstracts and




Fig. 1. PRISMA—Literature selection process.

read in full the text of 227 articles. Both researchers reviewed independently the articles and selected 44 publications that met the inclusion criteria of (1) the study explored the effect of a telerehabilitation and/or telemonitoring intervention, (2) in patients with a chronic lung disease, such as asthma, COPD, or COVID-19 patients, (3) and reported the effect of the intervention in one or more of the following outcomes: exercise capacity, physical activity, HRQoL, or healthcare use. The main reasons for exclusion of the studies included: (1) the study aimed to validate a new technological component instead of evaluating an intervention, (2) the intervention was only teleconsultation or one-time assessment, or the effect of the intervention in one of the (3) populations or (4) outcomes of interest were not reported.

Data extraction and synthesis

Information from the 44 articles was summarized in Table 1, which presented: (1) author(s)' name, (2) country of the study, (3) type of study, (4) intervention group and control group, (5) technology used in the study, (6) duration of the intervention, (7) participants' condition, and (8) description of the study population. The effect of telemonitoring and telerehabilitation on physical activity, exercise capacity, health-related quality of life and healthcare use in patients with chronic lung diseases or COVID-19 was extracted and compiled in Tables 2–4.

Results

All 44 manuscripts were original research published between 2005 and 2021. The studies were conducted in Australia (5), Canada (5), USA (5), Denmark (4), Italy (4), Spain (4), UK (4), China (3), the Netherlands (3), Ireland (2), New Zealand (1), Norway (1), Russia (1), Sweden (1), and 1 study in Austria, Germany, and Switzerland. The main characteristics of the included studies are presented in Table 1. Twenty-eight manuscripts reported on randomized controlled studies, 11 pre-post intervention studies, 2 matched population studies, 1 controlled non-randomized study, 1 quasi-randomized clinical trial, and 1 cohort study. Follow-up periods reported range between 10 days and 36 months. The number of participants involved in intervention groups of the studies ranged between 8 and 619 (median: 45). Thirty-five of the studies were conducted in patients with COPD, 5 in patients with asthma, 1 included patients with COPD and/or asthma, and 2 in patients with COVID-19. Two studies were conducted on children and the rest on adult patients (Table 1).

Interventions and technology

Table 1 describes the details of the interventions and the technology used. The effect of telemonitoring

(25 studies), telerehabilitation (8 studies) or both interventions combined (11 studies) were reported on the physical activity, exercise capacity, HRQoL and healthcare use of patients with respiratory diseases or COVID-19. These technology-enabled remote interventions were implemented as a stand-alone approach or in combination with other elements (e.g. standard care). Twenty-seven of the studies involved mobile apps, web pages, or virtual platforms accessed using a laptop, tablet or smartphone.^{39,41–44,46,47,49,55,59–61,63–69,71,72,74–76,79–81} In two studies the intervention was delivered using a teleconference platform,^{66,76} and one social platform.⁶⁷ Other transmitting devices/systems used in the studies included the health buddy device,^{40,51} the iRobi robot,⁷³ a PalmOne,⁴⁵ touch screen telemonitoring equipment,⁵⁷ a home health system connected to a phone line,⁵³ a computer-linked interactive phone tele-system,⁴⁸ a tele-modem,^{50,54,62,82} a satellite platform,⁸³ computer or push-bottom telephone,⁵⁸ handheld monitor connected to a phone line,⁵² a digital pen and health diary paper together with SMS.⁵⁶ Portable devices used to monitor patients' remotely included pulse oximeters (oxygen saturation and heart rate), spirometers (lung function), and accelerometers (physical activity) among others. Sixteen studies used more than one device to collect patient data. Information from the monitoring devices was collected using Bluetooth technology, manually entered, or verbally reported by participants to the research team or healthcare providers.

Exercise capacity and physical activity

A significant improvement in exercise capacity was reported in COVID-19 patients who received home-based telerehabilitation⁶⁴ (Table 2). Increased baseline exercise capacity was also found in COPD patients who received telemonitoring,⁵¹ telerehabilitation (3 of 4 studies),^{66,69,70} or a combination of both.^{76–78,81} However, only one study that explored the effect of telemonitoring⁵¹ and another that combined telemonitoring and telerehabilitation⁸¹ found greater improvement in exercise capacity in intervention groups compared to controls. Telerehabilitation^{76–78,81} alone or in combination with telemonitoring was not associated with changes in physical activity compared to control groups among COPD patients.^{66,71,81}

HRQoL and/or health status

Overall well-being improved in 83% of COVID-19 patients who participated in an intervention involving telerehabilitation and telemonitoring⁷⁵ (Table 3). Telemonitoring interventions were associated with an improvement in HRQoL in patients with asthma^{42,45,58,61,63} and COPD (4 of 6 studies),^{46,49,51,60} and no changes in HRQoL were identified in one study that included both asthma and COPD patients combined.⁴⁴ Nevertheless, when compared to

Table 1. Main characteristics of the studies included.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Telemonitoring												
Antoniades, Nick 2012 ³⁹ Australia	RCT	IG: Remote In-home monitoring (TeleMedCare) + standard best practice. CG: Standard best practice	Laptop (software), daily monitoring spirometry, vital functions, oximetry, etc.	Yes	12 Months	COPD	22	70 (10)	10 (83)	22	68 (9)	10 (83)
Au, David 2015 ⁴⁰ USA	Matched group design (1:1)	IG: Telehealth system combined with care management program (Health Buddy Program) CG: Matched to similar baseline characteristics	Four button Health Buddy device: asks for vital signs, disease symptoms, provides feedback, and categorizes patient's medical risk.	No	3 Years	COPD	619	75 (8)	338 (55)	619	74 (10)	338 (55)
Boer, Lonneke 2019 ⁴¹ Netherlands	RCT	IG: Smart mobile health tool for self-management (mHealth tool). CG: Paper action plan	Mobile phone (app), collected information on symptom changes and physiological measurements using a pulse oximeter, spirometer, and forehead thermometer.	Yes	12 Months	COPD	43	69 (8)	25 (58)	44	65 (8)	29 (66)
Chan, Debora 2007 ⁴² USA	RCT	IG: Internet-based home monitoring and education. CG: Office-based care	Home computer (website), camera and internet access. Digital video camera to capture patient's performance.	No	52 Weeks	Asthma	60	10 (3)	38 (63)	60	9 (3)	37 (62)
Chau, Janita 2012 ⁴³ Hong Kong	RCT	IG: Telecare service (ASTRI) + nurse home visit (education) CG: Only nurse home visit (education)	Mobile phone, respiratory rate sensor, pulse oximeter. Internet and wireless systems, databases and software for critical decision analysis, and support.	Yes	2 Months	COPD	22	73 (6)	21 (95)	22	72 (6)	18 (82)
Cushen, Brenda 2021 ⁴⁴ Ireland	Pre-post	GI: Community virtual ward model (patient information transferred to hospital portal)	Bluetooth-enabled smartphone and hospital portal. Remote monitoring of daily oxygen saturations, heart rate, and spirometry measurements.	Yes	Mean 10 (4) days admission to discharge	COPD and/or asthma	20	64 (13)	7 (35)	N/A	N/A	N/A

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
de Jongste, Johan 2009 ⁵ Netherlands	RCT	IG: Daily telemonitoring of exhaled nitric oxide + monitoring symptoms CG: Symptoms monitoring only	PalmOne, airway inflammation monitor (NIOX MINO; Aerocrine, Solna, Sweden) that measures FENO0.05	No	30 Weeks	Asthma	77	11 (2)	46 (60)	74	11 (4)	54 (73)
Deng, Ning 2020 ⁶ China	Pre-post	IG: Mobile health technology to deliver a community-based closed-loop management system (app)	MHealth system: smartphone (patient app), workstation (doctor), a cloud server, and a simple peak flow meter.	No	6 Months	COPD	39	61 (6)	36 (92)	N/A	N/A	N/A
Ding, Hang 2014 ⁷ Australia	Pre-post	IG: A mobile-phone-based home monitoring system (app)	Mobile phone to record COPD symptoms and vital signs on portal. Thermometer, pulse oximeter.	Yes	6 Months	COPD	10	65 (9)	5 (50)	N/A	N/A	N/A
Farias, Raquel 2019 ⁴⁸ Canada	Pre-post	IG: Phone interactive telesystem (computer-linked interactive phone telesystem)	Card (PIN) and the Telesystem contact information with automated phone call questions and a callback notification.	No	12 Months	COPD	256	70 (9)	117 (46)	N/A	N/A	N/A
Farmer, Andrew 2017 ⁴⁹ UK	RCT	IG: Digital health system (EDGE, Self-management, and support priorGramME). CG: Standard care	EDGE platform, tablet, and Bluetooth-enabled oximeter.	No	12 Months	COPD	110	69 (9)	68 (62)	56	69 (10)	34 (61)
Jódar-Sánchez, Francisco 2013 ⁵⁰ Spain	RCT	IG: Home telehealth program (Tele-Modem, Aerotel Medical Systems) CG: Usual care.	Spirometer, a pulse oximeter, heart rate, blood pressure monitor (model UA-767 BT, A&D Company). Data sent via a hub (Tele-Modem, Aerotel Medical Systems) connected to the patient's home telephone line.	Yes	4 Months	COPD	24	74 (8)	23 (96)	21	71 (10)	20 (95)
Koff, Patricia 2021 ⁵¹ USA	Quasi-randomized clinical trial	IG: Proactive iCare (healthcare delivery model that couples integrated care with remote monitoring) CG: Usual care	Health buddy, finger pulse oximeter, handheld pedometer.	Yes	9 Months	COPD	352	68 (8)	205 (58)	159	68 (9)	106 (67)

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Lewis, Keir E 2010 ⁵² UK	RCT	IG: Home telemonitoring (telemonitoring via the home telephone line) + standard care CG: Standard care	Handheld telemonitor connected via telephone line, thermometer, and pulse oximeter probe connected to the monitor.	Yes	6 Months	COPD	20	70 (range 61–73)	10 (50)	20	73 (range 63–79)	10 (50)
McDowell, Janet 2015 ⁵³ Ireland	RCT	IG: Home-based healthcare with telemonitoring (telecommunications device connected directly to patient's phone line) CG: Usual care	Home telehealth system (HomMed, Honeywell, USA) self-monitoring to record vital signs (finger probe and blood cuff) and answer questions.	Yes	6 Months	COPD	55	69 (7)	32 (58)	55	70 (7)	30 (54)
Pare, Guy 2013 ⁵⁴ Canada	RCT	IG: Home telemonitoring (touchscreen, modem) CG: Regular home care visits.	Touch screen with an integrated modem (TELUSTM) to send clinical data.	No	21.5 Months	COPD	60	67 (6)	19 (32)	60	68 (6)	19 (32)
Pedone, Claudio 2013 ⁵⁵ Italy	RCT	IG: Multiparametric telemonitoring of vital signs CG: Standard care	Cellular telephone coupled with wristband containing Bluetooth sensors (heart rate, physical activity, body temperature, and a pulse-oximeter).	No	9 Months	COPD	50	74 (6)	36 (72)	49	75 (6)	31 (63)
Persson, Hans 2020 ⁵⁶ Sweden	Cohort study	IG: Health Diary Telemonitoring and Hospital-Based Home Care (HBCH). CG: Clinical care.	Digital pen and a Health Diary paper form to report daily health status. Touchscreen Telemonitoring equipment to record and transmit daily questionnaires and monitor oxygen. Algorithms alerts.	No	12 Months	COPD	36	75 (6)	14 (39)	NA	NA	NA
Pinnock, Hilary 2013 ⁵⁷ UK	RCT	IG: Touch screen telemonitoring equipment + clinical care. CG: Clinical care.	Touchscreen Telemonitoring equipment to record and transmit daily questionnaires and monitor oxygen. Algorithms alerts.	No	12 Months	COPD	128	69 (8)	53 (41)	128	68 (8)	63 (49)
Rasmussen, Linda 2005 ⁵⁸ Denmark	RCT (3 groups)	IG: Internet-based monitoring asthma tool. CG1: Asthma specialist treatment CG2: General practitioner treatment	Internet diary or push-button phone. Peak flowmeter (Vitalograph, Ltd, Maid Moriton, Buckingham, United Kingdom).	No	6 Months	Asthma	85	28 (range 14–44)	27 (32)	CG1: 88 CG2: 80	CG1: 30 (range 19–45) CG2: 30 (range 20–45)	CG1: 30 (34) CG2: 30 (38)

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Schou, Lone 2013 ⁵⁹ Denmark	RCT	IG: telemedicine-based treatment (videoconferencing system-daily ward rounds) CG: conventional hospital admission	Touch screen PC and additional devices (pulse oximeter, spirometer, and thermometer) for monitoring the vital signs.	No	3 Months	COPD	22	68 (12)	10 (45)	22	73 (10)	8 (36)
Stamenova, Vess 2020 ⁶⁰ Canada	RCT (3 arms)	IG: Technology -Enabled remote monitoring program. CG1: Technology-Enabled Self-Management (web-based) CG2: Standard care	Web-based portal and Bluetooth devices: custom tablet computer pulse wave wrist cuff monitor, oximeter, weighing scale, and thermometer.	Yes	6 Months	COPD	41	71 (9)	23 (56)	CG1: 41 CG: 40	CG1: 71 (7) CG2: 72 (9)	CG1: 23 (56) CG2: 21 (52)
van Gaalen, Johanna 2013 ⁶¹ Netherlands	RCT (multicenter nonblinded, pragmatic randomized parallel controlled parallel trial)	IG: Internet-based self-management support. CG: Usual care.	Website platform. Handheld spirometer and reporting symptom score.	No	30 Months	Asthma	47	36 (8)	12 (26)	60	37 (8)	19 (32)
Vianello, Andrea 2016 ⁶² Italy	RCT	IG: Home telemonitoring (Gateway device for data transmission over telephone) CG: Usual care	TM system: finger pulse-oximeter and a gateway device for data transmission over a telephone line to a central data management unit located at the Veneto Regional e-Health Centre.	No	12 Months	COPD	230	75 (6)	164 (71)	104	76 (6)	76 (73)
Zajrina, Eilda 2015 ⁶³ Australia	RCT	IG: Telehealth program CG: Usual care	Mobile application Breathe-easy [®] supported by a Bluetooth-enabled handheld device (COPD-6R), which was used for self-monitoring of lung function.	No	6 Months	Asthma	36	31 (4)	0	36	31 (4)	0
Tele-rehabilitation Bermejo-Gil, Beatriz 2021 ⁶⁴ Spain	Pre-post	IG: Home-based tele-rehabilitation system (RespiraCon Nosotros)	Web application for respiratory exercises and chat function for interaction compatible with computer, tablet, television, and mobile.	No	1 Month	COVID-19	15	range 28-38	8 (53)	NA	NA	NA

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Burklow, Tajana 2015 ⁶⁵ Norway	Pre-post	IG: PR in home-based online groups (videoconference)	Internet-based comprehensive, multidisciplinary pulmonary rehabilitation program + step counter.	No	9 Weeks	COPD	10	61 (range 46-72)	5 (50)	N/A	N/A	N/A
Hansen, Henrik 2020 ⁶⁶ Denmark	RCT	IG: Pulmonary Telerehabilitation program (videoconference). CG: Conventional PR program	Videoconference software system installed on a single touch screen.	No	10 Weeks	COPD	67	68 (8)	32 (48)	67	68 (9)	28 (42)
Yuyu 2020 ⁶⁷ China	RCT	IG: Pulmonary internet explorer Rehabilitation (PeR) program based on social media (WeChat) CG: Face-to-face PR rehabilitation	PeR includes two ports: the computer end and the WeChat end.	No	3 Months	COPD	53	70 (6)	44 (83)	53	71 (7)	43 (81)
Jiménez-Reguera, Begoña 2020 ⁶⁸ Spain	RCT	IG: miHealth Web-Based platform (HappyAir) CG: Hospital scheduled evaluations.	HappyAir app: educational program and data collection related to physical activity and disease, recording medication intake, daily exercise time (minutes), level of tiredness and daily mood.	No	12 Months	COPD	20	68 (6)	9 (41)	24	68 (7)	13 (59)
Lewis, Adam 2021 ⁶⁹ UK	pre-post	IG: Online platform delivery of PR	E-learn Moodle platform (videoconference, messaging)	No	6 Weeks	COPD	17	69 (10)	8 (47)	NA	NA	NA
Sirickland, Michael 2011 ⁷⁰ Canada	RCT	IG: PR delivered via Telehealth CG: PR delivered in person (standard outpatient hospital-based program)	Videoconference	No	8 Weeks	COPD	147	69 (8)	78 (53)	262	69 (9)	125 (44)
Telemonitoring and telerehabilitation												
Benzo, Roberto 2021 ⁷¹ USA	RCT	IG: Home-based program with video-guided exercises (website) + phone call health coaching* CG: Waiting list 8 weeks and the intervention was offered afterwards	Computer tablet: video-guided exercises using an oximeter, an activity monitor and daily self-report of symptoms.	Yes	8 Weeks	COPD	72	69 (8)	34 (47)	74	68 (9)	37 (50)

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Bhatt, Surya 2019 ⁷² USA	Matched group design (1:2)	IG: Telehealth PR (video conference) * CG: Contemporaneous subjects who had been hospitalized for a COPD exacerbation but did not receive the intervention	Smartphone with video capabilities to facilitate two-way live videoconferencing. Automatic sphygmomanometers (blood pressure), and a pulse oximeter (heart rate and oxygen saturation).	Yes	12 Weeks	COPD	80	64 (10)	49 (61)	160	63 (11)	92 (57)
Broadbent, Elizabeth 2018 ⁷³ New Zealand	RCT	IG: iRobi robot (monitor health and prompt medical contact) CG: Standard care	Robot with Wi-Fi linked smart inhalers: (1) Measure pulse oximetry, forced expiration volume, heart rate, and symptoms, mental state, and functional status using the Clinical COPD Questionnaire (2) reminding medication and inhalers and record their adherence several times a day; (3) remind rehabilitation exercises (4) provide education about COPD; (5) I am feeling unwell function (6) trends over time health status and adherence.	No	4 Months	COPD	30	70 (10)	11 (37)	30	69 (9)	12 (40)
Galdiz, Juan 2021 ⁷⁴ Spain	RCT	IG: Pulmonary Telerehabilitation program (web-based platform) CG: Standard care	Web-based platform, and a telerehabilitation kit (mobile phone, pulse oximeter, dumbbells and exercise bicycle).	No	12 Months	COPD	46	62 (8)	30 (65)	48	63 (6)	33 (68)
Gilmutdinova, Ilmira R 2021 ⁷⁵ Russia	pre-post	IG: Telemedicine platform (COVIDREHAB)	A mobile phone, tablet or computer, an Internet connection and an e-mail address on this device. Platform: information and analytical system for remote monitoring of medical rehabilitation.	No	2 Weeks	COVID-19	178	50 (range 32–82)	70 (39)	NA	NA	NA

(continued)

Table 1. Continued.

Author Year Country	Type of study	Intervention Group (IG) Control Group (CG)	Technology	> 1 Monitoring devices involved (Yes/no)	Duration of the intervention	Disease	Intervention group			Control group		
							Number of participants	Age mean years (SD)	Males N (%)	Number of participants	Age Mean years (SD)	Males N (%)
Holland, Anne 2013 ⁶ Australia	Pre-post	IG: Telerehabilitation (video collaborative software)	A tablet computer was used for videoconferencing. A pulse oximeter (oxyhemoglobin saturation and heart rate).	No	8 Weeks	COPD	8	66 (range 56–83)	3 (38%)	NA	NA	NA
Marquis, Nicole 2015 ⁷⁷ Canada	Pre-post	IG: In-home PR (video conferencing system)	Videoconferencing system, internet connection with encrypted transmission. Wireless oximeter (oxygen saturation and heart rate).	Yes	6 Months (7.1)	COPD	23	65 (7.1)	8 (35)	NA	NA	NA
Paneroni, Mara 2015 ⁷⁸ Italy	controlled, non-randomized pilot study	IG: Telerehabilitation (satellite platform) CG: Standard outpatient rehabilitation program	Home telemonitoring platform, medical devices (oximeter, steps counter)	Yes	40 Days	COPD	18	6.5(10)	16 (89)	18	66 (6)	15 (83)
Rassouli, Frank 2018 ⁷⁹ Switzerland, Austria, and Germany	Observational (pre-post)	IG: Digital multidisciplinary PR (App)	Multiplatform smartphone application with exercise videos. Pedometer.	No	20 Days	COPD	34	59 (8)	8 (24)	NA	NA	NA
Ringbaek, Thomas 2015 ⁸⁰ Denmark	RCT	IG: Telehealth care (telemonitoring equipment) with the option of video consultation CG: Usual care	Tablet computer with a web camera, a microphone, and measurement equipment (spirometer, pulse oximeter, and bathroom scale).	Yes	6 Months	COPD	141	69 (9)	55 (39)	140	69 (10)	76 (54)
Tsai, Ling 2017 ⁸¹ Australia	RCT	IG: Home-based telerehabilitation (videoconferencing) CG: Usual care without exercise training	Computer with an in-built camera, and a finger-tip pulse oximeter.	Yes	8 Weeks	COPD	19	73 (8)	12 (63)	17	75 (9)	6 (86)
Vitacca, Michele 2009 ⁸² Italy	RCT	IG: Tele-assistance program (modem system through telephone line) CG: Standard care	Pulse oximetry device with solid memory card + modem telephone.	No	12 Months	COPD	57	61 (7)	NR	44	61 (17)	NR

SD: standard deviation; PR: pulmonary rehabilitation; SBP: standard best practice; N/A: not applicable; NR: not reported.

Table 2. Effect of telemonitoring and/or telerehabilitation on physical activity and exercise capacity in patients with lung diseases or COVID-19.

Disease	Study	Exercise capacity			Physical activity		
		IG change from pre-intervention	IG effect in comparison with CG	Instrument/tool used to assess the outcome	IG change from baseline	IG effect in comparison with CG	Instrument/tool used to assess the outcome
Telemonitoring	COPD	Koff, P. 2021 ⁵¹	↑	6MWT			
Telerehabilitation	COVID-19	Bermejo-Gil, B. 2021 ⁶⁴	↑	Borg scale			
	COPD	Hansen, Henrik 2020 ⁶⁶	↑	6MWT, 30 s sit-to stand test	no	=	Triaxial accelerometer
		Strickland, M. 2011 ⁷⁰	↑	12 min walk test			
		Lewis, A. 2021 ⁶⁹	↑	1 min sit-to stand test	NA		
		Jiménez-Reguera, B. 2020 ⁶⁸	no	6MWT	=		
Telerehabilitation and telemonitoring	COPD	Benzo, R. 2021 ⁷¹	↑	Endurance shuttle walk test	NR	=	ActiGraph Triaxial accelerometer
		Tsai, L. 2017 ⁸¹	↑	6MWT	no	=	
		Paneroni, M. 2015 ⁷⁸	↑	6MWT	=		
		Holland, A. 2013 ⁷⁶	↑	6MWT	=		
		Marquis, N. 2015 ⁷⁷	↑	6MWT	NA		
		Galdiz, J. 2020 ⁷⁴	↑	6MWT	NA		
			no	6MWT	=		

IG: Intervention group; CG: control group; 6MWT: 6-min walking test NA: not applicable. ↑: significantly better outcome; =: no significant difference in outcome change between groups. not reported. NR: data and/or significance level not reported.

Table 3. Effect of telemonitoring and/or telerehabilitation on health-related quality of life and/or health status in patients with lung diseases or COVID-19.

	Disease	Study	Health-related quality of life (HRQoL) and/or health status			
			IG change from pre-intervention	IG effect in comparison with CG	Instrument/tool used to assess the outcome	
Telemonitoring	Asthma	Rasmussen, L. 2005 ⁵⁸	↑	↑ (than the 2 CGs)	Asthma-related quality of life (AQLQ)	
		van Gaalen, J. 2013 ⁶¹	↑	↑	AQLQ	
		Zairina, E. 2015 ⁶³	↑	↑	mAQLQ (mini asthma quality of life questionnaire)	
		de Jongste, J. 2009 ⁴⁵	↑	=	Pediatric asthma caregiver quality of life questionnaire (PACQLQ)	
		Chan, D. 2007 ⁴²	↑	NR	Pediatric asthma quality of life questionnaires (PAQLQ) applied to caregiver	
	COPD and/or asthma COPD	Cushen, B. 2021 ⁴⁴	no	NA	EQ-VAS questionnaire	
		Koff, P. 2021 ⁵¹	↑	↑	SGRQ	
		Farmer, A. 2017 ⁴⁹	↑	↑	EQ-5D-5L questionnaire	
			↑	=	SGRQ	
		Stamenova, V. 2020 ⁶⁰	↑	= (in the 3 groups)	SGRQ	
		Deng, N. 2020 ⁴⁶	↑	NA	COPD assessment test (CAT)	
		Antoniades, N. 2012 ³⁹	no	=	Chronic respiratory disease questionnaire (CRDQ), 36-Item short form survey (SF-36)	
		Persson, H. 2020 ⁵⁶	no	NA	SGRQ	
		McDowell, J. 2015 ⁵³	NR	↑	SGRQ	
		Boer, L. 2019 ⁴¹	NR	=	EQ-5D questionnaire	
				NR	=	EQ-5D questionnaire, Nijmegen clinical screening instrument (NSCI), Clinical COPD Questionnaire (CCQ)
		Chau, J. 2012 ⁴³	NR	=	Chronic respiratory questionnaire (CRQ)	
		Jódar-Sánchez, F. 2013 ⁵⁰	NR	=	SGRQ, EuroQoL-5D questionnaire	
		Lewis, K. 2010 ⁶⁹	NR	=	SGRQ, and EuroQoL EQ-5D questionnaire	
Pinnock, H. 2013 ⁵⁷	NR	=	SGRQ			
Schou, L. 2013 ⁵⁹	NR	=	SGRQ			
Vianello, A. 2016 ⁶²	NR	=	SF-36			
Telerehabilitation	COPD	Stickland, M. 2011 ⁷⁰	↑	=	SGRQ	
		Burkow, T. 2015 ⁶⁵	↑	NA	SGRQ	
		Lewis, A. 2021 ⁶⁹	↑	NA	CRQ	
		Rassouli, F. 2018 ⁷⁹	↑	NA	CAT, CRQ	
		Jiang, Y. 2020 ⁶⁷	↑	=	CAT, SGRQ	
		Jiménez-Reguera, B. 2020 ⁶⁸	↑	=	SGRQ	
			no	=	CAT, EuroQoL-5D questionnaire	
Hansen, H. 2020 ⁶⁶	↑	=				

(continued)

Table 3. Continued.

	Disease	Study	Health-related quality of life (HRQoL) and/or health status		
			IG change from pre-intervention	IG effect in comparison with CG	Instrument/tool used to assess the outcome
Telerehabilitation and telemonitoring	COVID-19	Gilmudtinova, I. 2021 ⁷⁵	no	=	Clinical COPD Questionnaire (CCQ) EQ-5D-VAS Survey (Overall well-being improved in 83% of the participants)
			↑	NA	
	COPD	Holland, A. 2013 ⁷⁶ Marquis, N. 2015 ⁷⁷ Paneroni, M. 2015 ⁷⁸ Tsai, L. 2017 ⁸¹ Benzo, R. 2021 ⁷¹ Broadbent, E. 2018 ⁷³ Galdiz, J. 2020 ⁷⁴	↑	NA	CRQ
			↑	NA	CRQ
			↑	=	SGRQ
			↑	=	CAT
			no	=	CRDQ (Chronic respiratory disease Questionnaire)
			NR	=	CRQ
			NR	=	CCQ
			no	=	SF-36, Chronic respiratory disease Questionnaire (CRQ)

IG: Intervention group; CG: control group. NA: not applicable. EQ-VAS: EuroQol-visual analogue scales; CAT: COPD assessment test; SGRQ: St George's Respiratory Questionnaire; CRQ: chronic respiratory disease questionnaire; ↑: significantly better outcome; =: no significant difference in outcome change between groups. NR: data and/or significance level not reported.

control groups, telemonitoring was associated with a greater improvement in HRQoL only in 75% (3 of 4) of studies in asthma patients^{46,49,51,58,60,61,63} and in 23% (3 of 13) of studies in COPD patients.^{49,51,53} Telerehabilitation^{65–70,79} alone and the combination of telerehabilitation with telemonitoring^{76–78,81} were associated with improvement in HRQoL in COPD patients. However, no significant difference in HRQoL change was found between the intervention groups and controls.^{66–68,70,71,73,74,78,81}

Healthcare use

A decrease in pre-intervention hospital admissions, length of hospitalization, and visits to the emergency department and GP's office were reported in COPD patients who participated in telemonitoring interventions.^{47,48,51} Furthermore, 6 out of 13 studies reported fewer urgent visits to GP's office,⁵¹ fewer visits to the pulmonary specialist⁶² and nurse practitioner,⁴⁹ fewer hospital admissions,^{40,55} and readmissions,⁶² fewer days of hospitalization, and fewer ER visits⁵⁴ in patients with COPD who received telemonitoring compared to control groups. However, 7 of 13 studies found no significant difference in health care use between controls and patients with COPD,^{39,41,43,50,53,57,60} who participate in telemonitoring

interventions, and the same was reported in two studies among patients with asthma.^{42,63} No significant differences were found in COPD exacerbation-related hospital admission or in all causes of hospitalization between COPD participants of a telerehabilitation program compared with a conventional pulmonary rehabilitation (PR) program.⁶⁶ Three of 4 studies reported lower use of healthcare in COPD patients who participated in interventions combining telerehabilitation and telemonitoring compared with control groups.^{72,80,82}

Discussion

This paper aimed at portraying the use of telemonitoring and telerehabilitation in patients with chronic lung diseases such as asthma, COPD or COVID-19 patients and the effects of these modalities of intervention on physical activity, exercise capacity, health-related quality of life and healthcare use. A scoping review methodology was followed to explore the literature in the field. 27.3% of the studies retrieved were published after 2020 demonstrating the expanding need for technology in PR, especially after the rise of COVID-19. The first objective was to identify the telemonitoring and telerehabilitation interventions that are used to provide telehealth care for people with chronic respiratory conditions or

Table 4. Effect of telemonitoring and/or telerehabilitation on healthcare use in patients with lung diseases.

	Disease	Study	Healthcare use			
			IG change from pre-intervention	IG effect in comparison with CG	Instrument/tool used to assess the outcome	
Telemonitoring	Asthma	Chan, D. 2007 ⁴²	NR	=	Number of ED visits, hospitalizations, unscheduled asthma-related visits.	
		Zairina, E. 2015 ⁶³	NR	=	Number of unscheduled health-care visits.	
	COPD	Koff, P. 2021 ⁵¹		↓	↓	COPD-related urgent office GP visits (decreased only on IG).
				↓	=	COPD-related hospitalizations, hospital LOS, ED visits, ICU hospitalization.
				no	=	Non-COPD urgent office GP visits, hospitalizations, hospital LOS, ED visits, ICU hospitalizations.
				↓	NA	Hospital admissions, ED presentations, and GP visits.
		Ding, H. 2014 ⁴⁷		↓	NA	Respiratory-related ER visits, and COPD-related hospitalizations.
		Farias, R. 2019 ⁴⁸		NR	↓	Quarterly all-cause hospital admissions, respiratory-related hospital admissions.
		Au, D. 2015 ⁴⁰		NR	↓	Number of hospitalization days and visits to ER.
		Pare, G. 2013 ⁵⁴		NR	↓	COPD-related hospitalizations.
		Pedone, C. 2013 ⁵⁵		NR	↓	Visits to the GP practice nurses.
		Farmer, A. 2017 ⁴⁹		NR	=	Relative risk of hospital admission.
		Vianello, A. 2016 ⁶²		NR	↓	Readmission rate AECOPD and/or for any cause, appointment with a pulmonary specialist.
				NR	=	Hospitalization rate for AECOPD (acute exacerbations of COPD) and/or for any cause.
		Antoniades, N. 2012 ³⁹		NR	=	Number of COPD-admission/year, COPD-related length of stay (LOS) days/year, total admission/year, total LOS days/year.
		Boer, L. 2019 ⁴¹		NR	=	Exacerbation-related hospital admissions, unscheduled respiratory-related healthcare consultations.
Chau, J. 2012 ⁴³		NR	=	Number of emergency department visits and hospital re-admissions.		
Jódar- Sánchez, F. 2013 ⁵⁰		NR	=	ED visits, specialized consultations, hospitalizations.		
McDowell, J. 2015 ⁵³		NR	=	Number of ED visits, hospitalizations, or contacts with GP.		
Pinnock, H. 2013 ⁵⁷		NR	=	Hospital admissions due to COPD or all cause, duration of hospital admission.		
Stamenova, V. 2020 ⁶⁰		NR	=	Hospitalizations, ED visits, or clinic visits.		
Telerehabilitation	COPD	Hansen, H. 2020 ⁶⁶	NR	=	Hospital admission related to COPD exacerbations; all causes of hospitalization.	
Telerehabilitation and Telemonitoring	COPD	Bhatt, S. 2019 ⁷²	NR	↓	30-day all-cause readmission and	

(continued)

Table 4. Continued.

Disease	Study	Healthcare use		
		IG change from pre-intervention	IG effect in comparison with CG	Instrument/tool used to assess the outcome
	Vitacca, M. 2009 ⁸²	NR	↓	AECOPD (acute exacerbation of COPD) readmission.
	Ringbaek, T. 2015 ⁸⁰	NR NR	↓ =	Hospitalizations, ER admissions and urgent GP calls. Visits to the respiratory outpatient clinic.
	Broadbent, E. 2018 ⁷³	NR	=	Number of hospital admissions (for COPD or all causes), time to first admission, length of stay, visit to ER. Hospitalizations for respiratory problems, total number of days in hospital for respiratory problems.

IG: Intervention group; CG: control group. ED: emergency department; ER: emergency room; GP: general practitioner; ↓ significantly lower; = no significant difference between groups. NA: not applicable. NR: data and/or significance level not reported.

COVID-19. The literature review identified various technologies and technology-based approaches used to provide telemonitoring and/or telerehabilitation interventions for patients with asthma, COPD, or COVID-19. The technologies used were classified into two types. The first type included portable and mobile technologies to capture physiological and other non-invasive variables measured by patients themselves at home (e.g. heart rate, oxygen saturation) and the second type included information and communication technologies that allow seamless transfer of health data from the remote location to the healthcare provider. Overall, technologies were diverse, involved various levels of complexity, and were deployed in specific ways depending on the cases used. As such, we have classified the interventions into telemonitoring where only the surveillance of physiological and other non-invasive variables was needed, telerehabilitation where a PR or exercise intervention was administered remotely, or a combination of both.

The second objective of this paper was to provide an overview of the effects of telemonitoring and telerehabilitation on exercise capacity, physical activity, HRQoL, and healthcare use in patients with lung diseases or COVID-19. Results indicated that telemonitoring and telerehabilitation were associated with an improvement in exercise capacity, higher HRQoL, and lower healthcare use in these patients. Furthermore, these interventions produced outcomes comparable to standard care, which aligns with previous evidence that reported similar benefits of telerehabilitation to traditional in-person outpatient PR programs.^{84,85} Previous evidence has also suggested that telemonitoring interventions can contribute to better disease management, higher patient empowerment, higher

patient engagement and satisfaction, facilitate communication between the patient and healthcare team, and facilitate data collection and data access in patients with COPD.⁸⁶ Some potential barriers associated with these interventions included heterogeneity of care, lack of patient comfort with technology, patient resistance, time-consuming, increased workload for healthcare providers and staff shortages.⁸⁶ From the cost-effective perspective, evidence suggested that although technology-based interventions require an initial financial investment, they will substantially reduce costs in the long-term, potentially due to a reduction in healthcare use and travel costs.⁸⁷

Overall, evidence suggested that telemonitoring and telerehabilitation are potentially valuable mechanisms to improve patient care and access, especially in rural areas,⁸⁸ and do not increase mortality rates.⁸⁹ Therefore, policy and decision-makers should consider supporting the implementation of telemonitoring and telerehabilitation interventions by providing an initial investment associated with the cost of the equipment, regulating the practice of telerehabilitation including protected time for healthcare providers, and involving in-institution information and technology services to support data transmission and enable secure remote sessions.^{90,91} Future studies should explore mechanisms to reduce potential barriers associated with the use of technology-based interventions, such as lack of standardization and cost-effectiveness analyses.

Strengths and limitations

The results of this study contribute to filling a significant knowledge gap about the value of telemonitoring and telerehabilitation in the management of patients with chronic lung

diseases or COVID-19. This knowledge is needed among the first priorities identified by the patients and clinicians after COVID-19 widely affected the delivery of rehabilitation services.^{92,93} 63.6% of the retrieved manuscript reported on randomized controlled trials demonstrating the current need for evidence about the effectiveness of telemonitoring and telerehabilitation in patients with chronic lung diseases or COVID-19. This paper presented the evidence available as of June 2021. The generalizability of the results of this study may be influenced by the higher variability between the characteristics of the studies included such as the number and age of the patients, outcome measurements, length of the intervention, technological components involved, and additional elements included (e.g. education components, type and numbers of healthcare providers involved, etc.). Due to this heterogeneity, authors suggested a cautious interpretation of the results and compiled the studies characteristics in Table 1 to facilitate the readers' interpretation.

Conclusion

Telemonitoring and telerehabilitation interventions had a positive effect on patient exercise capacity and HRQoL and are associated with fewer healthcare use in patients with chronic lung diseases such as asthma, COPD, or post COVID-19. Furthermore, the results indicated that the outcomes of these interventions are comparable to standard care. Therefore, they are promising alternatives to support remote home-based rehabilitation in this group of patients that should be supported by policy and decision-making.

Acknowledgements

The authors would like to thank Yang Zhaoyun, Rachel Adodo, and Amarzish Qadeer for their contribution to article screening and data extraction.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


Funding

This work was supported by the start-up funds provided to Dr Sanchez-Ramirez by the University of Manitoba.

ORCID iDs

Diana C Sanchez-Ramirez  <https://orcid.org/0000-0003-1637-4309>

Hal Loewen  <https://orcid.org/0000-0003-3621-1304>

Mohamed-Amine Choukou  <https://orcid.org/0000-0001-9477-2412>

References

1. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease-Second Edition Sheffield: European Respiratory Society; 2017 [Available from:

Available from: https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf.

2. Johns Hopkins University of Medicine. COVID-19 Case Tracker. 2022 [Available from: Available from: <https://coronavirus.jhu.edu/>].
3. Hodgson CL, Higgins AM, Bailey MJ, et al. The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: A prospective cohort study. *Crit Care* 2021; 25: 382.
4. Sanchez-Ramirez DC, Normand K, Zhaoyun Y, et al. Long-term impact of COVID-19: A systematic review of the literature and meta-analysis. *Biomedicine* 2021; 9: 900.
5. DiBonaventura M, Paulose-Ram R, Su J, et al. The burden of chronic obstructive pulmonary disease among employed adults. *Int J Chron Obstruct Pulmon Dis* 2012; 7: 211–219.
6. Alghamdi F, Ashour A, Adeyemi L, et al. The psychological impacts of COVID-19 pandemic among emerging adults: An observational cross-sectional study. *Int J Environ Res Public Health* 2022; 19: 1445.
7. Corlade-Andrei M, Măirean C, Nedelea P, et al. Burnout syndrome among staff at an emergency department during the COVID-19 pandemic. *Healthcare* 2022; 10: 258.
8. Mapel DW, Dutro MP, Marton JP, et al. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. *BMC Health Serv Res* 2011; 11: 43.
9. Mulpuru S, McKay J, Ronksley PE, et al. Factors contributing to high-cost hospital care for patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 989–995.
10. NHLBI. National Heart, Lung, and Blood Institute/Pulmonary Rehabilitation [Available from: <https://www.nhlbi.nih.gov/health-topics/pulmonary-rehabilitation>].
11. Sanchez-Ramirez DC. Impact of pulmonary rehabilitation services in patients with different lung diseases. *J Clin Med* 2022; 11: 407.
12. Zhang H, Hu D, Xu Y, et al. Effect of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis of randomized controlled trials. *Ann Med* 2022; 54: 262–273.
13. Siddiq MAB, Rathore FA, Clegg D, et al. Pulmonary rehabilitation in COVID-19 patients: A scoping review of current practice and its application during the pandemic. *Turk J Phys Med Rehabil* 2020; 66: 480–494.
14. Corhay JL, Dang DN, Van Cauwenberge H, et al. Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. *Int J Chron Obstruct Pulmon Dis* 2014; 9: 27–39.
15. Lahham A and Holland AE. The need for expanding pulmonary rehabilitation services. *Life (Basel)* 2021; 11: 1236.
16. Milner SC, Boruff JT, Beaurepaire C, et al. Rate of, and barriers and enablers to, pulmonary rehabilitation referral in COPD: A systematic scoping review. *Respir Med* 2018; 137: 103–114.
17. Fischer MJ, Scharloo M, Abbink JJ, et al. Drop-out and attendance in pulmonary rehabilitation: The role of clinical and psychosocial variables. *Respir Med* 2009; 103: 1564–1571.
18. Keating A, Lee A and Holland AE. What prevents people with chronic obstructive pulmonary disease from attending pulmonary rehabilitation? A systematic review. *Chron Respir Dis* 2011; 8: 89–99.

19. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188: e13–e64.
20. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: A randomised, controlled equivalence trial. *Thorax* 2017; 72: 57–65.
21. Liu XL, Tan JY, Wang T, et al. Effectiveness of home-based pulmonary rehabilitation for patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. *Rehabil Nurs* 2014; 39: 36–59.
22. Rochester CL, Vogiatzis I, Holland AE, et al. An official American Thoracic Society/European Respiratory Society policy statement: Enhancing implementation, use, and delivery of pulmonary rehabilitation. *Am J Respir Crit Care Med* 2015; 192: 1373–1386.
23. Vitacca M, Montini A and Comini L. How will telemedicine change clinical practice in chronic obstructive pulmonary disease? *Ther Adv Respir Dis* 2018; 12: 1753465818754778.
24. Bjoernshave B, Korsgaard J and Nielsen CV. Does pulmonary rehabilitation work in clinical practice? A review on selection and dropout in randomized controlled trials on pulmonary rehabilitation. *Clin Epidemiol* 2010; 2: 73–83.
25. Bjoernshave B, Korsgaard J, Jensen C, et al. Participation in pulmonary rehabilitation in routine clinical practice. *Clin Respir J* 2011; 5: 235–244.
26. Maeder A. Telehealth and remote access. *Stud Health Technol Inform* 2010; 151: 239–254.
27. Murray E. Internet-delivered treatments for long-term conditions: Strategies, efficiency and cost-effectiveness. *Expert Rev Pharmacoecon Outcomes Res* 2008; 8: 261–272.
28. Polisen J, Tran K, Cimon K, et al. Home telehealth for chronic obstructive pulmonary disease: A systematic review and meta-analysis. *J Telemed Telecare* 2010; 16: 120–127.
29. Darkins A, Ryan P, Kobb R, et al. Care coordination/home telehealth: The systematic implementation of health informatics, home telehealth, and disease management to support the care of veteran patients with chronic conditions. *Telemed J E Health* 2008; 14: 1118–1126.
30. Kobb R, Chumbler NR, Brennan DM, et al. Home telehealth: Mainstreaming what we do well. *Telemed J E Health* 2008; 14: 977–981.
31. Field MJ. Telemedicine: A guide to assessing telecommunications in healthcare. *J Digit Imaging* 1997; 10: 28.
32. Schneider NM. Managing congestive heart failure using home telehealth. *Home Healthc Nurse* 2004; 22: 719–722.
33. Waqas A, Teoh SH, Lapão LV, et al. Harnessing telemedicine for the provision of health care: Bibliometric and scientometric analysis. *J Med Internet Res* 2020; 22: e18835.
34. Jong M, Mendez I and Jong R. Enhancing access to care in northern rural communities via telehealth. *Int J Circumpolar Health* 2019; 78: 1554174.
35. Brennan D, Tindall L, Theodoros D, et al. A blueprint for telerehabilitation guidelines. *Int J Telerehabil* 2010; 2: 31–34.
36. Ambrosino N, Vagheggini G, Mazzoleni S, et al. Telemedicine in chronic obstructive pulmonary disease. *Breathe (Sheff)* 2016; 12: 350–356.
37. Peretti A, Amenta F, Tayebati SK, et al. Telerehabilitation: Review of the state-of-the-art and areas of application. *JMIR Rehabil Assist Technol* 2017; 4: e7.
38. Andreu-Perez J, Leff DR, Ip HM, et al. From wearable sensors to smart implants—toward pervasive and personalized healthcare. *IEEE Trans Biomed Eng* 2015; 62: 2750–2762.
39. Antoniadis NC, Rochford PD, Pretto JJ, et al. Pilot study of remote telemonitoring in COPD. *Telemed J E Health* 2012; 18: 634–640.
40. Au DH, Macaulay DS, Jarvis JL, et al. Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2015; 12: 323–331.
41. Boer L, Bischoff E, van der Heijden M, et al. A smart Mobile health tool versus a paper action plan to support self-management of chronic obstructive pulmonary disease exacerbations: Randomized controlled trial. *JMIR Mhealth Uhealth* 2019; 7: e14408.
42. Chan DS, Callahan CW, Hatch-Pigott VB, et al. Internet-based home monitoring and education of children with asthma is comparable to ideal office-based care: Results of a 1-year asthma in-home monitoring trial. *Pediatrics* 2007; 119: 569–578.
43. Chau JP-C, Lee DT-F, Yu DS-F, et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. *Int J Med Inf* 2012; 81: 674–682.
44. Cushen B, Madden A, Long D, et al. Integrating hospital and community care: using a community virtual ward model to deliver combined specialist and generalist care to patients with severe chronic respiratory disease in their homes. *Ir J Med Sci* 2022; 191: 615–621.
45. de Jongste JC, Carraro S, Hop WC, et al. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. *American Journal of Respiratory & Critical Care Medicine* 2009; 179: 93–97.
46. Deng N, Chen J, Liu Y, et al. Using Mobile health technology to deliver a community-based closed-loop management system for chronic obstructive pulmonary disease patients in remote areas of China: Development and prospective observational study. *JMIR Mhealth Uhealth* 2020; 8: e15978.
47. Ding H, Karunanithi M, Kanagasigam Y, et al. A pilot study of a mobile-phone-based home monitoring system to assist in remote interventions in cases of acute exacerbation of COPD. *J Telemed Telecare* 2014; 20: 128–134.
48. Farias R, Sedeno M, Beaucage D, et al. Innovating the treatment of COPD exacerbations: A phone interactive telesystem to increase COPD action plan adherence. *BMJ Open Respir Res* 2019; 6: e000379.
49. Farmer A, Williams V, Velardo C, et al. Self-Management support using a digital health system compared with usual care for chronic obstructive pulmonary disease: Randomized controlled trial. *J Med Internet Res* 2017; 19: e144.
50. Jódar-Sánchez F, Ortega F, Parra C, et al. Implementation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. *Journal of Telemedicine & Telecare* 2013; 19: 11–17.
51. Koff PB, Min S-J, Freitag TJ, et al. Impact of proactive integrated care on chronic obstructive pulmonary disease. *Chronic Obstructive Pulmonary Diseases (Miami, Fla)* 2021; 8: 100–116.

52. Lewis KE, Annandale JA, Warm DL, et al. Home telemonitoring and quality of life in stable, optimised chronic obstructive pulmonary disease. *J Telemed Telecare* 2010; 16: 253–259.
53. McDowell JE, McClean S, FitzGibbon F, et al. A randomised clinical trial of the effectiveness of home-based health care with telemonitoring in patients with COPD. *J Telemed Telecare* 2015; 21: 80–87.
54. Pare G, Poba-Nzaou P, Sicotte C, et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: A randomized controlled trial. *European Research in Telemedicine* 2013; 2: 35–47.
55. Pedone C, Chiurco D, Scarlata S, et al. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: A randomized controlled trial. *BMC Health Serv Res* 2013; 13: 82.
56. Persson HL, Lyth J and Lind L. The health diary telemonitoring and hospital-based home care improve quality of life among elderly multimorbid COPD and chronic heart failure subjects. *Int J Chron Obstruct Pulmon Dis* 2020; 15: 527–541.
57. Pinnock H, Hanley J, McCloughan L, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. *BMJ (Clinical Research ed)* 2013; 347: f6070.
58. Rasmussen LM, Phanareth K, Nolte H, et al. Internet-based monitoring of asthma: A long-term, randomized clinical study of 300 asthmatic subjects. *J Allergy Clin Immunol* 2005; 115: 1137–1142.
59. Schou L, Ostergaard B, Rydahl-Hansen S, et al. A randomised trial of telemedicine-based treatment versus conventional hospitalisation in patients with severe COPD and exacerbation - effect on self-reported outcome. *J Telemed Telecare* 2013; 19: 160–165.
60. Stamenova V, Liang K, Yang R, et al. Technology-Enabled self-management of chronic obstructive pulmonary disease with or without asynchronous remote monitoring: Randomized controlled trial. *J Med Internet Res* 2020; 22: e18598.
61. van Gaalen JL, Beerthuisen T, van der Meer V, et al. Long-term outcomes of internet-based self-management support in adults with asthma: Randomized controlled trial. *J Med Internet Res* 2013; 15: e188.
62. Vianello A, Fusello M, Gubian L, et al. Home telemonitoring for patients with acute exacerbation of chronic obstructive pulmonary disease: A randomized controlled trial. *BMC Pulm Med* 2016; 16: 157.
63. Zairina E, Abramson MJ, McDonald CF, et al. Telehealth to improve asthma control in pregnancy: A randomized controlled trial. *Respirology (Carlton, Vic)* 2016; 21: 867–874.
64. Bermejo-Gil BM, Perez-Robledo F, Llamas-Ramos R, et al. Respiraconnosotros: A viable home-based telerehabilitation system for respiratory patients. *Sensors (Basel, Switzerland)* 2021; 21: 3318.
65. Burkow TM, Vognild LK, Johnsen E, et al. Comprehensive pulmonary rehabilitation in home-based online groups: A mixed method pilot study in COPD. *BMC Res Notes* 2015; 8: 766.
66. Hansen H, Bieler T, Beyer N, et al. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: A randomised multicentre trial. *Thorax* 2020; 75: 413–421.
67. Jiang Y, Liu F, Guo J, et al. Evaluating an intervention program using WeChat for patients with chronic obstructive pulmonary disease: Randomized controlled trial. *J Med Internet Res* 2020; 22: e17089.
68. Jimenez-Reguera B, Maroto Lopez E, Fitch S, et al. Development and preliminary evaluation of the effects of an mHealth web-based platform (HappyAir) on adherence to a maintenance program after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: Randomized controlled trial. *JMIR Mhealth Uhealth* 2020; 8: e18465.
69. Lewis A, Knight E, Bland M, et al. Feasibility of an online platform delivery of pulmonary rehabilitation for individuals with chronic respiratory disease. *BMJ Open Respir Res* 2021; 8.
70. Stickland M, Jourdain T, Wong EY, et al. Using telehealth technology to deliver pulmonary rehabilitation in chronic obstructive pulmonary disease patients. *Can Respir J* 2011; 18: 216–220.
71. Benzo RP, Ridgeway J, Hoult JP, et al. Feasibility of a health coaching and home-based rehabilitation intervention with remote monitoring for COPD. *Respir Care* 2021; 66: 960–971.
72. Bhatt SP, Patel SB, Anderson EM, et al. *Video telehealth pulmonary rehabilitation intervention in chronic obstructive pulmonary disease reduces 30-day readmissions*. New York, New York: American Thoracic Society, 2019, pp.511–513.
73. Broadbent E, Garrett J, Jepsen N, et al. Using robots at home to support patients with chronic obstructive pulmonary disease: Pilot randomized controlled trial. *J Med Internet Res* 2018; 20: e45.
74. Galdiz JB, Gomez A, Rodriguez D, et al. Telerehabilitation programme as a maintenance strategy for COPD patients: A 12-month randomized clinical trial. *Arch Bronconeumol* 2021; 57: 195–204.
75. Gilmudtinova IR, Kolyshekov VA, Lapickaya KA, et al. Telemedicine platform COVIDREHAB for remote rehabilitation of patients after COVID-19. *Eur J Transl Myol* 2021; 31: 9783.
76. Holland AE, Hill CJ, Rochford P, et al. Telerehabilitation for people with chronic obstructive pulmonary disease: Feasibility of a simple, real time model of supervised exercise training. *J Telemed Telecare* 2013; 19: 222–226.
77. Marquis N, Larivee P, Saey D, et al. In-Home pulmonary telerehabilitation for patients with chronic obstructive pulmonary disease: A Pre-experimental study on effectiveness, satisfaction, and adherence. *Telemed J E Health* 2015; 21: 870–879.
78. Paneroni M, Saleri M, Vitacca M, et al. Is telerehabilitation a safe and viable option for patients with COPD? A feasibility study. *COPD: Journal of Chronic Obstructive Pulmonary Disease* 2015; 12: 217–225.
79. Rassouli F, Boutellier D, Duss J, et al. Digitalizing multidisciplinary pulmonary rehabilitation in COPD with a smartphone application: An international observational pilot study. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 3831–3836.
80. Ringbaek T, Green A, Laursen LC, et al. Effect of tele health care on exacerbations and hospital admissions in patients with

- chronic obstructive pulmonary disease: A randomized clinical trial. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 1801–1808.
81. Tsai LLY, McNamara RJ, Moddel C, et al. Home-based tele-rehabilitation via real-time videoconferencing improves endurance exercise capacity in patients with COPD: The randomized controlled TeleR study. *Respirology (Carlton, Vic)* 2017; 22: 699–707.
 82. Vitacca M, Bianchi L, Guerra A, et al. Tele-assistance in chronic respiratory failure patients: A randomised clinical trial. *Eur Respir J* 2009; 33: 411–418.
 83. Paneroni M, Simonelli C, Vitacca M, et al. Aerobic exercise training in very severe chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Am J Phys Med Rehabil* 2017; 96: 541–548.
 84. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. *Cochrane Database Syst Rev* 2021; 1 : CD013040.
 85. Snoswell CL, Chelberg G, De Guzman KR, et al. The clinical effectiveness of telehealth: a systematic review of meta-analyses from 2010 to 2019. *J Telemed Telecare* 2021. DOI: 10.1177/1357633X211022907.
 86. Kruse C, Pesek B, Anderson M, et al. Telemonitoring to manage chronic obstructive pulmonary disease: systematic literature review. *JMIR Med Inform* 2019; 7: e11496.
 87. Seto E. Cost comparison between telemonitoring and usual care of heart failure: A systematic review. *Telemed J E Health* 2008; 14: 679–686.
 88. Venter A, Burns R, Hefford M, et al. Results of a telehealth-enabled chronic care management service to support people with long-term conditions at home. *J Telemed Telecare* 2012; 18: 172–175.
 89. Snoswell CL, Stringer H, Taylor ML, et al. An overview of the effect of telehealth on mortality: A systematic review of meta-analyses. *J Telemed Telecare* 2021. DOI: 10.1177/1357633X211023700.
 90. Smith AC, Thomas E, Snoswell CL, et al. Telehealth for global emergencies: Implications for coronavirus disease 2019 (COVID-19). *J Telemed Telecare* 2020; 26: 309–313.
 91. Thomas EE, Haydon HM, Mehrotra A, et al. Building on the momentum: Sustaining telehealth beyond COVID-19. *J Telemed Telecare* 2022; 28: 301–308.
 92. Leochico CFD, Rey-Matias BMV and Rey-Matias RR. Telerehabilitation perceptions and experiences of physiatrists in a lower-middle-income country during the COVID-19 pandemic. *Pm r* 2022; 14: 210–216.
 93. Werneke MW, Deutscher D, Grigsby D, et al. Telerehabilitation during the COVID-19 pandemic in outpatient rehabilitation settings: A descriptive study. *Phys Ther* 2021; 101: pzab110.